Antibody Affinity Precipitation Using Protein Nanoscaffolds
By addressing the limitations of traditional methods, this nanoparticle-based affinity precipitation technology offers a cost-effective, scalable, and recyclable solution, making it an attractive option for pharmaceutical and biotech companies.
Technology
Monoclonal antibodies (mAbs) are becoming increasingly crucial in the biopharmaceutical industry, driving significant advancements in upstream production that have led to markedly higher antibody yields in large-scale bioreactors. This surge in production has placed considerable pressure on downstream purification processes, particularly the traditionally used Protein A affinity chromatography. Despite its high selectivity and yield, Protein A chromatography struggles with scalability and cost-effectiveness. In response, affinity precipitation has emerged as a promising non-chromatographic alternative, offering several operational advantages. This method involves binding a target protein to a ligand, applying an environmental stimulus to precipitate the complex, separating insoluble from soluble components, and using a second stimulus to elute the target protein. Conventional affinity precipitation processes that require high temperature and salt concentrations which can lead to antibody aggregation and denaturation. An emerging avenue to address these challenges is the use of enhanced capturing scaffolds .UD Researchers have developed a protein nanoparticle to serve as an ideal scaffold, assembling into large structures that can be functionalized at multiple sites. This method is capable of specifically binding to target proteins in solution. Upon binding, the nanoparticle-protein complex precipitates out of the solution, allowing for straightforward separation and recovery. This method has been optimized to minimize the exposure of environmentally responsive recombinants to high temperatures and salt concentrations.By addressing the limitations of traditional methods, this nanoparticle-based affinity precipitation technology offers a cost-effective, scalable, and recyclable solution, making it an attractive option for those seeking efficient antibody purification processes.
Benefits
- Cost-effective and easily scalable
- An improvement over current ELP-based affinity precipitation and Protein A chromatography
- Our structures are easily recyclable and yield over a 95% recovery of human IgG antibodies
Applications
- Life Science Research Product Companies
- Lab Service Companies
- Biologics Manufacturing Companies
- Biotech Companies
- Pharmaceutical Companies
Additional info
The technology is covered by US patent 11,149,060 with fully preserved U.S. patent rights available for licensing.